alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

2D SESSION H. R. 8057 

To designate the facility of the United States Postal Service located at 

9317 Bolsa Avenue in Westminster, California, as the ‘‘Little Saigon 

Vietnam War Veterans Memorial Post Office’’. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 17, 2024 

Mrs. STEEL (for herself, Mr. SCHIFF, Ms. LEE of California, Mr. SHERMAN, 

Mr. ISSA, Mr. VALADAO, Mr. LAMALFA, Mr. SWALWELL, Mr. 

OBERNOLTE, Mr. COSTA, Mr. GOMEZ, Mr. PANETTA, Mr. DUARTE, Mr. 

HARDER of California, Ms. CHU, Mr. CALVERT, Mr. MULLIN, Mr. 

CORREA, Mr. DESAULNIER, Mr. MIKE GARCIA of California, Mr. LEVIN, 

Mr. THOMPSON of California, Mr. KHANNA, Mr. ROBERT GARCIA of California, Mr. CARBAJAL, Ms. JACOBS, Mr. PETERS, Ms. KAMLAGER-DOVE, 

Mr. LIEU, Mrs. KIM of California, Ms. LOFGREN, Mr. VARGAS, Ms. 

BROWNLEY, Ms. ESHOO, Mr. MCCLINTOCK, Mr. KILEY, Ms. BARRAGA ́N, 

and Mr. AGUILAR) introduced the following bill; which was referred to the 

Committee on Oversight and Accountability 

A BILL 

To designate the facility of the United States Postal Service 

located at 9317 Bolsa Avenue in Westminster, California, 

as the ‘‘Little Saigon Vietnam War Veterans Memorial 

Post Office’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 8057 IH

1 SECTION 1. LITTLE SAIGON VIETNAM WAR VETERANS ME2 MORIAL POST OFFICE. 

3 (a) DESIGNATION.—The facility of the United States 

4 Postal Service located at 9317 Bolsa Avenue in West5 minster, California, shall be known and designated as the 

6 ‘‘Little Saigon Vietnam War Veterans Memorial Post Of7 fice’’. 

8 (b) REFERENCES.—Any reference in a law, map, reg9 ulation, document, paper, or other record of the United 

10 States to the facility referred to in subsection (a) shall 

11 be deemed to be a reference to the ‘‘Little Saigon Vietnam 

12 War Veterans Memorial Post Office’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
From: West, Jeffrey L

To: Kordzi, Joe

Subject: Response to information Request - Tolk Station - Docket No. EPA-R06-OAR-2014-0754

Date: Thursday, August 20, 2015 4:25:05 PM

Attachments: Xcel Response to EPA Information Request on EPA Proposed Rule on Texas Regional Haze - Docket No. EPA-R06-

OAR-2014-0754.pdf

Joe:

Please find attached a response to your questions regarding water use/availability and mercury

controls at Tolk Station. Additionally, in this letter we have formally requested that this letter to be

added to the docket. A hard copy will follow via US mail. Please let me know if you have any

questions.

Jeff West

Xcel Energy | Responsible By Nature

Director, Environmental Services

1800 Larimer Street, Suite 1300, Denver, CO 80202

P: 303-571-2762 C: 806-570-8914 F: 303-294-2859

E: Jeffrey.L.West@xcelenergy.com
<Page>

                                                                    EXHIBIT 10.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         I, Claude Helie, Interim Chief Financial Officer of Quebecor Media Inc.
(the "Company"), have reviewed the Annual Report of the Company on Form 20-F for
the period ending December 31, 2002 as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), and based on the inquiries I have
made or caused to be made in the fulfillment of my responsibilities as the Chief
Financial Officer of the Company, I hereby certify, pursuant to 18 U.S.C.
ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that
for the periods covered by the Report:

         (1) the Report fully complies with the requirements of Section 13(a) of
the Securities Exchange Act of 1934; and

         (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


                                            /s/ Claude Helie
                                            -----------------------------------
                                            Claude Helie
                                            Interim Chief Financial Officer
                                            March 31, 2003


A signed original of this written statement required by Section 906 has been
provided to Quebecor Media Inc. and will be retained by Quebecor Media Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.

THIS CERTIFICATE IS BEING MADE FOR THE EXCLUSIVE PURPOSE OF COMPLIANCE BY THE
CHIEF FINANCIAL OFFICER OF THE COMPANY WITH THE REQUIREMENTS OF SECTION 906, AND
SHALL NOT BE DEEMED TO BE A PART OF THE REPORT OR FILED FOR ANY OTHER PURPOSE.
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

AMBAR WIBOWO,

 Petitioner,

 v.

ERIC H. HOLDER, Jr., Attorney General,

 Respondent.

No. 06-72334

Agency No. A079-643-138

MEMORANDUM*

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted February 15, 2011** 

Before: CANBY, FERNANDEZ, and M. SMITH, Circuit Judges. 

Ambar Wibowo, a native and citizen of Indonesia, petitions for review of the

Board of Immigration Appeals’ order dismissing his appeal from an immigration

judge’s decision denying his application for asylum, withholding of removal, and

protection under the Convention Against Torture (“CAT”). We have jurisdiction

FILED

MAR 08 2011

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 06-72334

under 8 U.S.C. § 1252. We review for substantial evidence factual findings,

Wakkary v. Holder, 558 F.3d 1049, 1056 (9th Cir. 2009), and we deny the petition

for review.

Even if Wibowo timely filed his asylum application, substantial evidence

supports the agency’s conclusion that Wibowo did not establish that he was or

would be persecuted on account of an actual or imputed political opinion. See INS

v. Elias-Zacarias, 502 U.S. 478, 481 n.1 (1992); see also Sangha v. INS, 103 F.3d

1482, 1489-91 (9th Cir. 1997). Accordingly, Wibowo’s asylum and withholding

of removal claims fail. See Ochoa v. Gonzales, 406 F.3d 1166, 1172 (9th Cir.

2005).

Finally, substantial evidence supports the agency’s denial of CAT relief

because Wibowo failed to establish it is more likely than not that he would be

tortured if returned to Indonesia. See Wakkary, 558 F.3d at 1068.

PETITION FOR REVIEW DENIED.
#### § 1.1232-2 [Reserved]
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5965 Subcutaneous, implanted, intravascular infusion port and catheter. ( a ) *Identification.* A subcutaneous, implanted, intravascular infusion port and catheter is a device that consists of a subcutaneous, implanted reservoir that connects to a long-term intravascular catheter. The device allows for repeated access to the vascular system for the infusion of fluids and medications and the sampling of blood. The device consists of a portal body with a resealable septum and outlet made of metal, plastic, or combination of these materials and a long-term intravascular catheter is either preattached to the port or attached to the port at the time of device placement. The device is available in various profiles and sizes and can be of a single or multiple lumen design.
( b ) *Classification.* Class II (special controls) Guidance Document: “Guidance on 510(k) Submissions for Implanted Infusion Ports,” FDA October 1990.
[65 FR 37043, June 13, 2000]
#### § 1.1442-3 Tax exempt income of a foreign tax-exempt corporation.

For regulations providing for a claim of exemption for income exempt from tax under section 501(a) of a foreign tax-exempt corporation, see § 1.1441-9. See § 1.1443-1 for withholding rules applicable to foreign private foundations and to the unrelated business income of foreign tax-exempt organizations.

[T.D. 8734, 62 FR 53466, Oct. 14, 1997]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1460 Nystagmograph. ( a ) *Identification.* A nystagmograph is a device used to measure, record, or visually display the involuntary movements (nystagmus) of the eyeball.
( b ) *Classification.* Class II (performance standards).
Letter Agreement of Edward M. Hurwitz and ACLARA BioSciences, Inc.



 
EXHIBIT 10.38

 
[GRAPHIC REMOVED HERE] 
 
November 27, 2002 
Ed Hurwitz 
177 Watkins Ave 
Atherton, CA 94027 
 
Dear Ed, 
 
This letter supplements your employment
letter dated October 29, 2002. It is agreed that in the event that your service on the board of directors does not extend beyond the current term (which ends at the 2003 annual shareholders meeting) you will continue to provide advice and
consultation in an employment capacity to ACLARA BioSciences, Inc. for a period of two years (which period is referred to herein as the “Additional Period”). Your options will cease to vest but will continue to be exercisable during the
Additional Period. No cash compensation will accrue during the Additional Period, and your services will be limited to being available for advice and consultation up to a maximum of four hours per month. 
 
Sincerely, 
 
/s/  Thomas Baruch 
Thomas Baruch 
Chairman 
 

	 Accepted:      /s/ Edward
Hurwitz            
	 	 Date:        12/12/02
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 96-2245

MELDON S. HOLLIS, JR.,

Plaintiff - Appellant,

versus

ROBERT GORDON; TYDINGS & ROSENBERG,

Defendants - Appellees.

Appeal from the United States District Court for the District of

Maryland, at Baltimore. William M. Nickerson, District Judge.

(CA-96-2474-WMN)

Submitted: February 13, 1997 Decided: February 25, 1997

Before WIDENER and HAMILTON, Circuit Judges, and BUTZNER, Senior

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Meldon Stonewall Hollis, Jr., Appellant Pro Se. Frederick Charles

Leiner, TYDINGS & ROSENBERG, Baltimore, Maryland, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Appellant appeals the district court's order dismissing his

civil suit to enjoin the enforcement of a state court judgment and

denying his motion for a temporary restraining order. We have

reviewed the record and find no reversible error. Accordingly, we

affirm the district court. Hollis v. Gordon, No. CA-96-2474-WMN

(D. Md. Aug. 20, 1996). We dispense with oral argument because the

facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional

process.

AFFIRMED
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.5575 Neuromuscular tongue muscle stimulator for the reduction of snoring and obstructive sleep apnea. ( a ) *Identification.* A neuromuscular tongue muscle stimulator for the reduction of snoring and obstructive sleep apnea consists of a removable intraoral mouthpiece that uses electrodes to deliver neuromuscular stimulation to the tongue to strengthen tongue musculature to reduce snoring and obstructive sleep apnea.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Performance testing must demonstrate the wireless compatibility, electrical safety, battery safety, and electromagnetic compatibility of the device in its intended use environment.
( 2 ) Software verification, validation, and hazard analysis must be performed.
( 3 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 4 ) Patient labeling must include: ( i ) Information on device components, setup, and use of the device including placement of sensors and mouthpieces, and images or illustrations;
( ii ) A summary of technical specifications;
( iii ) Instructions on how to clean and maintain the device;
( iv ) A statement that the patient should maintain regular follow up visits with dentist and sleep specialist; and
( v ) A statement that patients should have a comprehensive dental examination prior to using this device.
( 5 ) A human factors assessment must evaluate simulated use of the device to demonstrate that the user can correctly use device based on the labeling and instructions for use.
[89 FR 71154, Sept. 3, 2024]
[Federal Register Volume 75, Number 46 (Wednesday, March 10, 2010)]
[Notices]
[Page 11229]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4958]


=======================================================================
-----------------------------------------------------------------------

UNITED STATES INSTITUTE OF PEACE


Notice of Meeting

    Date/Time: Tuesday, March 16, 2010. 11 a.m.-12 p.m.
    Location: 1200 17th Street, NW., Suite 200, Washington, DC 20036-
3011.
    Status: Board Executive Session--Portions may be closed pursuant to 
Subsection (c) of section 552(b) of Title 5, United States Code, as 
provided in subsection I 706(h)(3) of the United States Institute of 
Peace Act, Public Law 98-525.
    Agenda: March 16, 2010 Board Executive Session. Approval of Board 
Resolutions; Transition discussions.
    Contact: Tessie F. Higgs, Executive Assistant, Telephone: (202) 
429-3836.

    Dated: March 3, 2010.
Tara Sonenshine,
Executive Vice President, United States Institute of Peace.
[FR Doc. 2010-4958 Filed 3-9-10; 8:45 am]
BILLING CODE 6820-AR-P
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A) THE
REGISTRANT'S FORM 10-QSB FOR THE QUARTER ENDED JUNE 30, 1998 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH (B) FORM 10-QSB.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1
<CURRENCY> US DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<EXCHANGE-RATE>                                      1
<CASH>                                         584,051
<SECURITIES>                                   234,248
<RECEIVABLES>                                  929,799
<ALLOWANCES>                                    48,000
<INVENTORY>                                    696,000
<CURRENT-ASSETS>                             2,433,640
<PP&E>                                       5,422,535
<DEPRECIATION>                               1,459,224
<TOTAL-ASSETS>                               6,413,881
<CURRENT-LIABILITIES>                        1,303,020
<BONDS>                                        771,483
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,396,316
<OTHER-SE>                                   2,905,240
<TOTAL-LIABILITY-AND-EQUITY>                 6,413,881
<SALES>                                      3,324,992
<TOTAL-REVENUES>                             3,344,500
<CGS>                                        1,399,363
<TOTAL-COSTS>                                1,169,559
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              48,660
<INCOME-PRETAX>                                726,918
<INCOME-TAX>                                   281,552
<INCOME-CONTINUING>                            445,366
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   445,366
<EPS-PRIMARY>                                      .12
<EPS-DILUTED>                                      .12
        

</TABLE>
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1650 Image-intensified fluoroscopic x-ray system. ( a ) *Identification.* An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.
( b ) *Classification.* Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
[53 FR 1567, Jan. 20, 1988, as amended at 66 FR 57369, Nov. 15, 2001; 84 FR 71818, Dec. 30, 2019]
§ 522.90c Ampicillin sodium. ( a ) *Specifications.* Each milliliter of aqueous solution constituted from ampicillin sodium powder contains 300 milligrams (mg) ampicillin equivalents.
( b ) See Nos. 042791 and 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount* : 3 mg per pound of body weight twice daily by intravenous or intramuscular injection.
( 2 ) *Indications for use.* For the treatment of respiratory tract infections (pneumonia and strangles) due to *Staphylococcus* spp., *Streptococcus* spp. (including *S. equi*), *Escherichia coli*, and *Proteus mirabilis*, and skin and soft tissue infections (abscesses and wounds) due to *Staphylococcus* spp., *Streptococcus* spp., *E. coli*, and *P. mirabilis*, when caused by susceptible organisms.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[72 FR 45158, Aug. 13, 2007, as amended at 79 FR 16184, Mar. 25, 2014; 86 FR 57997, Oct. 20, 2021]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.2050 Staphylococcal typing bacteriophage. ( a ) *Identification.* A staphylococcal typing bacteriophage is a device consisting of a bacterial virus intended for medical purposes to identify pathogenic staphylococcal bacteria through use of the bacteria's susceptibility to destruction by the virus. Test results are used principally for the collection of epidemiological information.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25045, June 12, 1989; 66 FR 38790, July 25, 2001]
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 99-6012

UNITED STATES OF AMERICA, Plaintiff - Appellee, versus ROBERT G. WRIGHT, Defendant - Appellant.Appeal from the United States District Court for the Western District of Virginia, at Roanoke. Jackson L. Kiser, Senior District Judge. (CR-89-113-R, CA-98-693-R) Submitted: March 2, 1999 Decided: April 16, 1999 Before NIEMEYER and HAMILTON, Circuit Judges, and BUTZNER, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Robert G. Wright, Appellant Pro Se. Thomas Jack Bondurant, Jr., Assistant United States Attorney, Roanoke, Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Robert G. Wright appeals the district court’s order denyinghis motion to reconsider. We have reviewed the record and the district court’s opinion and find no reversible error. Accordingly, we deny a certificate of appealability and dismiss the appeal on the reasoning of the district court. See United States v. Wright ,Nos. CR-89-113-R; CA-98-693-R (W.D. Va. Dec. 17, 1998). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1410 Electroencephalograph electrode/lead tester. ( a ) *Identification.* An electroencephalograph electrode/lead tester is a device used for testing the impedance (resistance to alternating current) of the electrode and lead system of an electroencephalograph to assure that an adequate contact is made between the electrode and the skin.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9.
[44 FR 51730, Sept. 4, 1979, as amended at 61 FR 1123, Jan. 16, 1996; 66 FR 38807, July 25, 2001]
#### § 1.1239-2 Gain from sale or exchange of depreciable property between certain related taxpayers on or before October 4, 1976.

Section 1239 provides in general that any gain from the sale or exchange of depreciable property between a husband and wife or between an individual and a controlled corporation on or before October 4, 1976 (and in the case of a sale or exchange occurring after that date if made under a binding contract entered into on or before that date), shall be treated as ordinary income. Thus, any gain recognized to the transferor from a sale or exchange after May 3, 1951, and on or before October 4, 1976 (or thereafter if pursuant to a binding contract entered into on or before that date), directly or indirectly, between a husband and wife or between an individual and a controlled corporation, of property which, in the hands of the transferee, is property of a character subject to an allowance for depreciation provided in section 167 (including such property on which a deduction for amortization is allowable under sections 168 and 169) shall be considered as gain from the sale or exchange of property which is neither a capital asset nor property described in section 1231. For the purpose of section 1239, a corporation is controlled when more than 80 percent in value of all outstanding stock of the corporation is beneficially owned by the taxpayer, his spouse, and his minor children and minor grandchildren. For the purpose of this section, the terms *children* and *grandchildren* include legally adopted children and their children. The provisions of section 1239(a)(2) are applicable whether property is transferred from a corporation to a shareholder or from a shareholder to a corporation.

[T.D. 6500, 25 FR 12021, Nov. 26, 1960, as amended by T.D. 7569, 43 FR 51388, Nov. 3, 1978]
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, August 25, 2020. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, August 25, 2020 The Court of Appeals hereby passes the following order A21I0014. MID-AMERICA APARTMENTS, LP et al. v. GENEVIEVE LAMBERT EMERSON et al. .
Upon consideration of the Application for Interlocutory Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 19A00800